Medicine · 2018 · 57 citations · 4 references
MedicineOrthopaedic SurgeryOrthopedic SurgeryMusculoskeletal InfectionOrthopedic Sports MedicineOrthopedicsBone InfectionsHip DisordersHip InjuriesJoint InfectionsMusculoskeletal PathologyOrthopedic ExaminationSystemic Infection SymptomsTraumatic Musculoskeletal InfectionWhite Blood Cell Imaging
INTRODUCTION: Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is an autoinflammatory disorder without standardized treatment. Janus kinase (JAK) inhibitors can block a range of cytokines and might possess significant anti-inflammatory activity. Here, we report the first case of efficacious treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib. CASE PRESENTATION: A 44-year-old woman presented with arthralgia in the right wrist and complained of having difficulty in doing housework. Symptoms were unresponsiveness to nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, and tumor necrosis factor inhibitors. A diagnosis of SAPHO syndrome was made based on previous dermatological and osteoarticular manifestations and bone scintigraphy findings. Oral treatment with tofacitinib at 5 mg twice daily in combination with the basic methotrexate treatment was initiated. After 4 weeks of using tofacitinib, the patient reported marked improvement of symptoms and also reported being competent in completing housework. CONCLUSIONS: The efficacy of JAK inhibitors in treating refractory SAPHO syndrome should be noted.
4
[Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases].
A M Chamot, C.L. Benhamou, Marcel-Francis Kahn et al. · PubMed · 1987 · 392 citations
Medicine, Dermatology, Pathology +11
IL-23/Th17 targeted therapies in SAPHO syndrome. A case series
Daniel Wendling, F. Aubin, Frank Verhoeven et al. · Joint Bone Spine · 2017 · 92 citations
Life Sciences, Immunology, Pathology +13